RDT impact on Treatment pattern and outcomes in patients with CR Pathogens- Competitive Research Grant
Pfizer Research & Development is a key contributor to scientific breakthroughs, with more than 414 million patients reached globally with our medicines and vaccines in 2024
This competitive program is designed to evaluate potential differences with the application of Rapid Diagnosis Tests (RDTs) on treatment pattern and clinical outcomes in patients with carbapenem-resistant organisms (CR) pathogens, with a focus on departments, such as Intensive Care Unit (ICU), respiratory, infectious disease, hematology, solid organ transplantation (SOT) etc.
Research focuses on following areas concerning patients with CR pathogens:
• To describe the RDTs used during the study and patients’ baseline characteristics.
• To compare the mean time from specimen receipt to test results and receipt of appropriate antimicrobial therapy.
• To compare the percentage of patients receiving appropriate antimicrobial therapy within 24-48h.
• To describe the treatment pattern (drug, duration, changes in empiric therapy etc) based on RDTs and routine culture.
• To describe clinical outcomes, including ICU admission, hospital length of stay (LoS), clinical cure rate, 30-day all-cause mortality , microbiological result etc.
• To explore the association between RDT utilization and improved clinical outcomes.
Individual projects requesting up to $42,000 will be considered. The estimated total available budget related to this RFP is $350,000.
• Project length is 12 – 36 months.
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.